Zydus Lifesciences Q1 Results: Net Profit Rises 3.3% YoY to Rs 1,466.8 Cr; Shares Slip Despite Strong US Sales

Shares of Zydus Lifesciences Ltd. erased early gains in Tuesday's trading session after the company reported its June quarter results. While the earnings surpassed analyst expectations, the performance appeared subdued on a year-on-year basis, leading to muted investor sentiment.

Zydus Lifesciences Q1 Results 2026: Net Profit, Revenue Increase

Zydus Lifesciences on Tuesday announced its financial results for the first quarter of the financial year 2025-26 (Q1 FY26), posting a steady rise in both profit and revenue. The pharmaceutical major reported a 3.3% year-on-year (YoY) increase in consolidated net profit, which climbed to Rs 1,466.8 crore in Q1 FY26 from Rs 1,419.9 crore in the same quarter of the previous financial year.

The company also saw an improvement in its top line. Revenue from operations rose by 5.9% YoY, reaching Rs 6,573.7 crore in Q1 FY26, up from Rs 6,207.5 crore in Q1 FY25. The growth was largely driven by new drug launches in the United States market, which continues to be a key region for Zydus in terms of business performance and strategic expansion.

Zydus Lifesciences Share Price Today: Stock Reaction After Q1 Earnings Announcement

As of 2:18 PM on Tuesday, shares of Zydus Lifesciences were trading at Rs 953, down around 1.3% from the previous close. The stock opened at Rs 955.55, hit an intraday high of Rs 969.00, and fell to a low of Rs 948.00 during the session. Currently, the stock is trading nearly 26.6% below its 52-week high of Rs 1,298.00, but still about 19.9% above its 52-week low of Rs 795.00.

Zydus Lifesciences EBITDA FY26

In its Q1 FY26 earnings report, Zydus Lifesciences reported a flat EBITDA (Earnings Before Interest, Tax, Depreciation and Amortisation) at Rs 2,089 crore, showing little change compared to the same period last year. However, this figure exceeded analysts' expectations, which were pegged at around Rs 1,879.3 crore, indicating better-than-anticipated cost control and operating performance.

Despite the EBITDA beating estimates, EBITDA margins came under pressure, contracting by nearly 200 basis points year-on-year. The margin stood at 31.8% in Q1 FY26, down from 33.6% in Q1 FY25. Still, the reported margin was higher than the street's forecast of 29.6%, offering some relief to investors concerned about profitability trends.

US Sales in Upside Momentum

On the revenue front, US sales, a critical segment for Zydus-remained largely stable when compared to the year-ago period. Sequentially, sales from the US grew 2.5% over the March 2025 quarter, reaching $372 million. This modest uptick was driven by new drug launches and steady demand for existing products in the highly competitive US generic drug market.

Commenting on the Q1 performance, Sharvil Patel, the Managing Director of Zydus Life said, "Our Q1 FY26 performance reflects the results of our disciplined execution, with most of our key businesses meeting expectations. We remain firmly on track to achieve our FY26 aspirations and are excited about the upcoming developments on the innovation front, which we believe will open up new avenues for sustainable growth."